trial · primary record
VYD2311
Long COVID
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 130 |
| Primary completion | 2027-06 |
| Primary endpoint | Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90 |
| Registry ID | NCT07899346 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:14.383Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07899346
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.